Cargando…

Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma

Accumulating evidence shows a close association between various types of bile acids (BAs) and hepatocellular carcinoma (HCC), and they have been revealed to affect tumor immune response and progression mainly by regulating Farnesoid X receptor (FXR). Nevertheless, the roles of Norcholic acid(NorCA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Yihang, Li, Kun, Qin, Yunfei, Zeng, Kaining, Liu, Jianrong, Huang, Shaozhuo, Chen, Yewu, Yu, Haoyuan, Liu, Wei, Ye, Linsen, Yang, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648605/ https://www.ncbi.nlm.nih.gov/pubmed/34888230 http://dx.doi.org/10.3389/fonc.2021.711448

Ejemplares similares

Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells
por: He, Jialin, et al.
Publicado: (2015)

NTF3 Correlates With Prognosis and Immune Infiltration in Hepatocellular Carcinoma
por: Liu, Rongqiang, et al.
Publicado: (2021)

Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma
por: Li, Wenli, et al.
Publicado: (2019)

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
por: Liu, Xijun, et al.
Publicado: (2015)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Progress of MRI Radiomics in Hepatocellular Carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2021)

Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor
por: Xu, Wenjing, et al.
Publicado: (2022)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis
por: LIAN, FAN, et al.
Publicado: (2015)

Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
por: Jiang, Longying, et al.
Publicado: (2023)

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC
por: Li, Kun, et al.
Publicado: (2022)

Prediction model for hepatocellular carcinoma recurrence after hepatectomy: Machine learning-based development and interpretation study
por: Liu, Rongqiang, et al.
Publicado: (2023)

Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma
por: Qi, Feng, et al.
Publicado: (2021)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
por: Ikpa, Pauline T., et al.
Publicado: (2019)

Investigating the Role of Farnesoid X Receptor in Heme Biosynthesis and Ductular Reaction
por: Dean, Angela E, et al.
Publicado: (2021)

Stimulation of the farnesoid X receptor promotes M2 macrophage polarization
por: Jaroonwitchawan, Thiranut, et al.
Publicado: (2023)

Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN
por: LIU, JUN, et al.
Publicado: (2014)

Antibiotic pretreatment attenuates liver ischemia–reperfusion injury by Farnesoid X receptor activation
por: Liu, Hanyi, et al.
Publicado: (2022)

TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma
por: Bao, Shixiang, et al.
Publicado: (2021)

Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells
por: Kainuma, Masahiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e9jnc1ou6bm05oe3isev5jammd